Turk Kardiyol Dern Ars. Ahead of Print: TKDA-62678 | DOI: 10.5543/tkda.2018.62678
Mid-term clinical outcomes of new generation drug eluting stents for treatment of diffuse coronary artery disease
, Davran Çiçek1
, Sinan Akıncı1
, Serhat Balcıoğlu1
, Cihan Altın2
, Haldun Müderrisoğlu31
Başkent University Hospital, Alanya Medical and Research Center, Cardiology Department, Alanya2
Başkent University Hospital, İzmir Zübeyde Hanım Medical and Research Center, Cardiology Department, İzmir3
Başkent University Hospital, Cardiology Department, Ankara
OBJECTIVES Diffuse coronary artery disease displays a challenging issue in clinical Cardiology practice. There are limited data about percutaneous revascularization of these patients.
METHODS Our study is an observational clinical evaluation and patients with diffuse coronary artery disease revascularized with new generation drug eluting stents (DES) were searched retrospectively. Patients treated with multiple, overlapping new generation DES (at least 60mm in length per vessel) has been included. We investigated major adverse cardiac events (MACE) at the end of 1st year following the index procedure. MACE was defined as cardiac death, stent thrombosis, non-fatal myocardial infarction and target lesion revascularization (TLR).
RESULTS We enrolled a total of 71 patients (with 75 coronary vessels) treated with new generation DES for diffuse coronary artery disease in our study. Zotarolimus DES were used in 48 vessels and Biolimus A9 DES were used in 27 vessels. Median total stent length per vessel was 75.0mm (60.0-106.0) and median number of stents implanted was 3 (2-4) for each vessel. Cumulative incidence of MACE at the end of 1st year was 11.2% (8 patients). Presence of diabetes mellitus and ST segment elevated myocardial infarction (STEMI) were defined as independent clinical risk factors related to MACE development.
CONCLUSION Coronary artery revascularization with new generation drug eluting stents can be a good choice in the treatment of selected patients with diffuse coronary artery disease. Diabetes mellitus and STEMI were found to be related to worse clinical outcomes with this treatment option in our study.
Diffuse coronary artery disease, Drug eluting stents, Percutaneous coronary intervention
How to cite this article
Corresponding Author: Ali Çoner, Türkiye